Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 535 matches for

With Ochre Bio's chemistry laboratory housed at The Oxford Science Park, it was a no-brainer for the company to move over to the park when it outgrew the BioEscalator.

Pile of moving boxes

Akimbo Bio crosses the bridge from academia to industry as it joins the BioEscalator

The BioEscalator is pleased to welcome Akimbo Bio to its community of innovative bioscience start-ups. Co-founded by two Oxford researchers, the company is developing a next-generation immunotherapy platform that leverages intelligent receptor crosstalk to enhance both the efficacy and safety of cancer treatments.

Spectre Bio moves from computation to the lab as it joins the BioEscalator

The BioEscalator is delighted to welcome Spectre Bio to its start-up community. The company joins us as it transitions from computational research to laboratory-based development, bringing an exciting new immunomodulatory platform to the BioEscalator ecosystem.

Icosphere Biosciences appoints Dr John Beadle as Non-Executive Director

Dr Beadle brings a remarkable track record of leading biotechnology companies, guiding teams from early discovery through to successful clinical translation.

U-Ploid Biotechnologies wins Femtech competition award at the Carlos Simón Foundation for research in women’s health

U‑Ploid, a biotechnology company developing first-in-class therapeutics to tackle age-related infertility, has been awarded the Femtech Competition Award at the Femtech Pitch Showcase & Competition organised by the Carlos Simón Foundation for Research in Women’s Health, a leading institution advancing scientific excellence in reproductive medicine.

Abbott to acquire Exact Sciences

Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments.

Prior Labs and Oxford Cancer Analytics partner to advance liquid biopsy and clinical decision making in lung disease

Prior Labs is collaborating with Oxford Cancer Analytics (OXcan) to apply TabPFN to high-clinical-need lung diseases, focusing on more accurate differentiation across complex disease stages.

Ochre Bio completes human liver functional genomics and single-cell datasets in partnership with GSK

Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, today announced the successful completion of the research phase of its collaboration with GSK, delivering two comprehensive functional genomics and single-cell human liver datasets.

Oxford Cancer Analytics secures new space at Inventa to accelerate diagnostic innovation

Oxford Cancer Analytics (OXcan), a fast-scaling diagnostics company, has committed to a new lease of 2,400 square feet at Mission Street and BGO’s Inventa building in Oxford’s West End. OXcan is continuing its growth trajectory, moving from the BioEscalator to Inventa and joining a growing number of innovation companies in the emerging central cluster.

PepGen announces issuance of U.S. Patent for proprietary PGN-EDODM1 molecule

The Composition of Matter patent covers the Company’s novel PGN-EDODM1 molecule and serves as a cornerstone of its expanding patent portfolio.

Nucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal Cell

Groundbreaking research using Nucleome MCC technology reveals complex structure of DNA inside living cells at base pair resolution for the first time, pioneering a new approach to identify new drug targets from human genetics.

Enara Bio’s DARKFOX discovery propels ENA101, the first ever bispecific T Cell engager targeting a cancer-specific dark antigen, into IND-enabling studies

Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens® and the development of bispecific T cell engagers for solid tumours, will unveil its newly discovered cancer-specific target DARKFOX™ as the first in a new category of validated Dark Antigens in an oral presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 annual meeting. SITC 2025 is being held on November 5-9 in National Harbor, MD.

Partnership with CyanoCapture Ltd to develop bionanotechnology for targeted drug delivery

The University of Liverpool rand CyanoCapture Ltd are joining forces to develop the next generation of carboxysome-based targeted drug delivery systems, exploiting unique traits found in fast-growing cyanobacteria.

Alethio Therapeutics launches with new CEO and Chair to advance two targeted medicines for Myeloproliferative Neoplasms (Chronic Blood Cancers)

Leveraging deep scientific and clinical expertise in MPNs, the company aims to drive a pipeline of disease-modifying precision therapies that selectively target disease-driving cells. Progress is being made with AT-01, a first-in-class antibody-drug conjugate (ADC) program, which has strong preclinical validation and is advancing toward IND/CTA-enabling studies anticipated to start in the first half of 2026. Additionally, AT-02 expands the ADC portfolio by targeting mutant CALR, a key driver mutation in MPNs. The leadership and board have been strengthened with the appointments of Dr. Rohit Batta as CEO and Mike Grey as Chair.

U-Ploid presents first Lyvanta™ data demonstrating reduction of aneuploidy in aged oocytes at ASRM 2025

U-Ploid is today presenting its first scientific abstract, “Preclinical testing of a novel therapeutic for reduction of aneuploidy in oocytes,” at the 2025 American Society for Reproductive Medicine (ASRM) Annual Meeting in San Antonio, Texas. The study showcases preclinical data on Lyvanta™ (UP-085), a novel therapeutic designed to reduce chromosome segregation errors in oocytes associated with maternal age.

MediMabBio secures KRW 25.6B in Series B funding to advance pipeline and global partnerships

MediMabBio has successfully raised KRW 25.6B (USD $17M) in its Series B financing round. The newly secured capital will be used to expand strategic global partnerships for accelerated business development and the advancement of follow-on programs.

Exogene Graduates from the BioEscalator

We are delighted to celebrate the graduation of Exogene as it transitions from the BioEscalator to its new home at the Wood Centre for Innovation.

Simon Meier will be joining Oxford Cancer Analytics (OXcan) as Incoming Interim CEO

Simon brings over two decades of strategic leadership and investment expertise across diagnostics, biotech, and digital health innovation.

MediMabBio Wins 1st Place at Japan’s “Innovation Tiger 2025”

MediMabBio won first place at Innovation Tiger 2025, a global biotech startup competition held at Shonan iPark in Japan. The final round featured 16 companies selected from 79 applicants across Korea, Japan, and Taiwan.

Dr. Peter Jianrui Liu to step down as CEO of Oxford Cancer Analytics Ltd (OXcan)

Dr. Peter Jianrui Liu, Co-Founder of OXcan, has decided to step down from his role as the Company’s Founding CEO, to pursue other interests. He will remain a significant shareholder in the Company and therefore will retain every interest in the Company’s development and success as an advisor.

Professor Heidi Johansen-Berg joins the BioEscalator Management Board

We are delighted to welcome Professor Heidi Johansen-Berg to our Management Board, an expert in brain imaging and neuroplasticity, and a champion of innovation in the life sciences.

Load More

Similar stories